Actively Recruiting
Phase 1 Study to Understand How Kidney Problems Affect the Bodys Handling of GL0034 in Adults with Type 2 Diabetes
Led by Sun Pharmaceutical Industries Limited · Updated on 2026-03-13
40
Participants Needed
3
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how kidney problems affect the way the body processes GL0034, a long-acting drug used for Type II Diabetes Mellitus. This Phase 1 open-label study will include about 40 adults with varying levels of kidney function, including those with normal kidneys and those with moderate to severe kidney impairment, some on dialysis. The goal is to understand if kidney health changes the drug levels in the body and to guide safe dosing for patients with kidney issues. Participants will receive a single subcutaneous dose of GL0034. They will be grouped based on kidney function normal, moderate impairment, severe impairment without dialysis, and severe impairment with dialysis. Blood samples will be taken at multiple times over 672 hours after dosing to study the drugs presence in the body. The study will also watch for any side effects or safety concerns during the trial. During the study, participants will undergo blood sampling to measure drug levels and safety checks up to five weeks after dosing. Researchers will monitor for any adverse events or serious side effects. The total study participation involves screening, dosing, multiple blood draws, and follow-up visits to assess how the drug behaves in people with different kidney functions and to ensure their safety throughout the trial.
CONDITIONS
Brief Title
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Research Team
H
Head Regulatory Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here